vision one agenda · 11.00 session chair introduction 11.05 early embryo viability assessment of...
TRANSCRIPT
Helping to realizethe dream of parenthood
VISION
Fertility
ONE AGENDANovel individualized treatment approaches to reduce time to live birthSaturday 5th & Sunday 6th, May 2018 Shanghai, China
Scientific Committee: Professor Zi-Jiang Chen (China)Professor Luk Rombauts (Australia)Professor Filippo Ubaldi (Italy)
Helping to realizethe dream of parenthood
VISION
ONE AGENDANovel individualized treatment approaches to reduce time to live birth
Saturday 5th & Sunday 6th May 2018
Learning objectives
• Be more aware that placing the patient at the center of fertility treatment decisions maximizes the outcomes of reproductive therapy
• Have increasing knowledge of novel approaches which reduce time to live birth and therefore decrease treatment dropout rate
• Learn how to optimize time to live birth with drugs and fertility technologies
• Liaise with a wide range of experts in the field to help stimulate discussion with and education of other members of working clinical practice teams
Day 1 - Saturday May 5th
08.30 Welcome and meeting objectives
08.40 Keynote lecture: “How does female and male age affect embryo quality?” Zi-Jiang Chen
SESSION 1: Ovarian reserve evaluation and prediction of ovarian response
09.10 Session chair introduction
09.15 Improve the prediction of ovarian reserve and response in ART using biomarkers Christos Venetis
09.35 Optimize FSH starting and adapting dose COS to improve reproductive outcomes (OPR, LBR, CLBR) Sesh Sunkara
09.55 Panel discussion
10.30 Tea break
SESSION 2: Individualized stimulation protocol
11.00 Session chair introduction
11.05 Individualization of COS: Where are we in 2018? Human Fatemi
11.25 Mild stimulation? Let’s move away from the past Nicolaos Polyzos
11.45 Redefining poor responder patients: Facts and myths Carlo Alviggi
12.05 Panel discussion
12.30 Lunch break
ART, assisted reproductive technology; CLBR, cumulative live birth rate; COS, controlled ovarian stimulation; FET, frozen embryo transfer; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; HRT, hormone replacement therapy; IVF, in vitro fertilisation; LBR, live birth rate; LPS, luteal phase support; OHSS, ovarian hyperstimulation syndrome; OPR, ongoing pregnancy rates; PGT, preimplantation genetic testing.
Helping to realizethe dream of parenthood
VISION
Day 1 - Saturday May 5th Day 2 - Sunday May 6th
SESSION 3: Optimal LPS and the endometrial receptivity
13.35 Session chair introduction
13.40 New trends in oocyte triggering and how we can individualize LPS in fresh cycles Anusch Yazdani
14.00 Optimal LPS protocol in FET cycle (natural cycle, HRT cycle) Rong Li
14.20 Endometrial receptivity and progesterone rise: How can we handle that? Chung Hoon Kim
14.40 Panel discussion
15.20 Tea break
SESSION 4: Change and development in laboratory
15.50 Session chair introduction
15.55 Changes and challenges in the IVF laboratory Dean Morbeck
16.15 Embryo cryopreservation strategy from clinic to laboratory Yanwen Xu
16.35 Panel discussion
17.00 Close day 1
18.30 Dinner
08.30 Keynote lecture: Can we eradicate OHSS? Antonio Pellicer
SESSION 5: How to shorten time to live birth
09.00 Session chair introduction
09.05 Personalized stimulation protocols to shorten time to live birth Qi Yu
09.25 Embryo transfer during ovarian stimulation cycle or during delayed FET cycle in normal responders: Balancing efficiency and safety to shorten time to live birth Sesh Sunkara
09.45 Down-regulation approaches with respect to time to live birth (GnRH agonist versus GnRH antagonist) Hong Ye
10.05 Panel discussion
10.30 Tea break
SESSION 6: Embryo assessment and PGT
11.00 Session chair introduction
11.05 Early embryo viability assessment of human embryos for transfer Shehua Shen
11.25 Clinical outcomes in preimplantation genetic screening/diagnosis for aneuploidies Ge Lin
11.45 Panel discussion
12.10 Wrap up of the conference with all Scientific Committee members
12.30 Buffet lunch
If you would like to register for this meeting please email: [email protected]
GBPMLR/NONF/1117/0064c The information contained herein is not for distribution in the USA and Canada.